Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Leo had mentioned a possible addition to the board. Did he say anything to you about it? If so when do you think it would happen? Do you think it would be a science person, industry or finance person? Thanks
Pivot week? From a trading perspective or are you expecting more news?
Thanks for the English lesson! Hopefully it will help us scratch an itch for our share price.
Do you know of another way to do preclinical work?
They have locations all over. Rochester is the mother ship and not just a satellite.
I agree TD
Thanks but when they are only dosing once a week they must realize that the results wouldn't be optimized so why continue enrolling really sick patients if they aren't seeing any benefit?
NR, what are your thoughts on K now that you have met with management and heard the presentation?
NR, what is your take on K after speaking with management and listening to the talk? It seems to me DF is holding on to the phase 1 trial for a long time. Thanks
Both days I think really shows your conviction and willingness to put up with a lot of sh&t on red days!
It is interesting to see who posts on red days and who posts on green days. Almost two different boards. I prefer green days!
BK, what is your take on what was said about K today? Thanks
So in your opinion the RPDD and the 2 OD designations aren't news or signs of progress?
Yes riskier is a good word. I like it. Hopefully we can reduce the risk some more in the next 6months
I have found I get my message across and the post will be around for awhile.
I was being sarcastic ! LOL
So let me see if I understand; investing in publicly traded companies can be risky. Wow. That's good thanks.
Third party validation can also be a big name board appointment or an article in the paper but these also have costs. I agree a bad deal is not good yet this company needs 3rd party validation. The B QIDP gave us that validation that ultimately got the company noticed and the share price up.
A partnership implies third-party validation. A partnership reduces future dilution.
I agree whoops. I think the market is looking for certainty around revenue and a partnership would be a huge step in the right direction. I think this would be a good question/commit for NR to ask management next week.
If it's not public information then why don't you ask Leo and tell us what you find out?
I don't think it would be appropriate to speculate where and when B will be used at this piont.
IMO the market is looking for certainty regarding revenue whether in the former of a partnership or approval and the market is looking for third party verification(this could be a great board appointment or article). Hopefully either or both of these comes soon.
Doctors aren't sure why or how an infection will seed in a total joint but it can happen at any time. I know total joint patients are given antibiotics before dental procedures to help prevent an infection.
Yes infections are a big problem when they happen. They are difficult to treat and can happen at any time (2 days after surgery or 10 years). The biofilm issue is very real and is one of the primary reasons they are so difficult to treat.
Another intriguing thing about total joints is how they're being reimbursed. The government and some insurance companies are starting to give the providers a bundled payment which means they are responsible for all care for 90 days. So if the patient developed an infection in that 90 day period it would cost them a lot of money. An implant with a lower risk of infection would be a nice advantage.
Actually they could do a lot of testing. Any thing that is implanted must be sterilized and packaged which is obviously an important part of the process.
It could be Depuy because as you know Depuy is a division of J&J. If it worked for one of their products it could be applied to many of J&J's products. Infections for total joints are very expensive and potential devastating for the patient.
Again, give us examples. Thanks
Great piont. How about gleevac. Never even reached the end of the trial.
Excellent point. That is why when they were given all the information they awarded k multiple program awards. See it's not hard just follow the evidence.
Again no evidence just comments.
I don't think the market will care where it is published as long as the results are good.
Nov. 10 pr. We are pleased to report that we have submitted our first paper on Kevetrin and p53 for peer-review and publication at a relevant scientific journal. Now that significant clinical data has been collected on Kevetrin, it’s time for us to begin publishing in peer-reviewed journals to complement the peer-reviewed data presented at oncology conferences. - See more at: http://cellceutix.com/cellceutix-files-form-10-q-for-quarter-ended-september-30-2015/#sthash.7z0KtfM7.dpuf
Happy Thanksgiving everyone!
I am sure you are right, wishful thinking on my part.
Don't have a clue but I hope it's because they are throwing in the towel.
Don't know but if you push the red button in the upper left corner they aren't listed and they were listed on this list not to long ago.
The piont is that it's not on their website.
It's always been 100 participants.